Exchange Surveillance
No active ASM or GSM measures on this stock.
Price band — none
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
DiviS Laboratories Ltd is engaged in the manufacture of Active Pharma Ingredients (APIs) and intermediates. The company in a matter of short time expanded their breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.They are actively involved in developing alternate, patent non-infringing processes for APIs, for the inventors to manage late life cycle and leading generic drug manufacturers.The company`s product range includes Bupropion Hbr,Bupropion HCL,Capecitabine,Carbidopa,Desloratadine,Dexlansoprazole /(R)-Lansoprazole,Irbesartan,Levodopa,Niacin,Sibutramine HCL,Valacyclovir HCL,Valsartan,Venlafaxine HCL,VerapamiL HCL,Vigabatrin,Zolpidem Tartrate ,etc
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- Hyderabad, Telangana
- Chairman
- Ramesh B V Nimmagadda
- CEO & MD
- Murali K Divi
- Registrar
- KFIN Technologies Pvt. Ltd.
- Exchange
- NSE
- ISIN
- INE361B01024
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Divis Laboratories Ltd today?
Divis Laboratories Ltd (DIVISLAB) is trading at ₹8,950. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is DIVISLAB’s P/E ratio versus the sector?
DIVISLAB trades at a P/E of 82.3. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is DIVISLAB’s dividend yield?
DIVISLAB has a dividend yield of 0.32%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is DIVISLAB’s 52-week high and low?
DIVISLAB has traded between ₹5,647.5 and ₹9,740 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Divis Laboratories Ltd?
Divis Laboratories Ltd has a market capitalisation of ₹2.46 lakh crore.
▶What is DIVISLAB’s return on equity?
DIVISLAB reports a return on equity of 16.8%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.
▶Who are DIVISLAB’s competitors?
The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is DIVISLAB’s promoter holding?
Promoters hold 51.87% of DIVISLAB. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include DIVISLAB?
Index membership is listed in the Context block on this page, along with the weight DIVISLAB carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Divis Laboratories Ltd a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from DIVISLAB’s own numbers. The judgement is yours.
DIVISLAB at a glance
Divis Laboratories Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector. Divis Laboratories Ltd (DIVISLAB) last traded at ₹8,950, giving it a market capitalisation of ₹2.46 lakh crore. The 52-week range is ₹5,647.5 to ₹9,740, and the price is 81% of the way up that range. It trades at a price-to-earnings ratio of 82.3. Promoters hold 51.87% of the company in the latest shareholding filing.
| Market cap | ₹2.46 lakh crore |
|---|---|
| P/E | 82.3 |
| ROE | 16.8% |
| ROCE | 22.4% |